SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as shareholders push for leadership changes and express frustration over slumping sales, high inventory levels, and a perceived disconnection from modern consumer trends. The market is deeply divided ahead of its earnings release, with a significant cohort of traders actively shorting the stock, while others view its recent descent to multi-year lows as a potential, though highly risky, entry point for a long-term turnaround.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with the community closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high as retail participants anticipate a potential valuation re-rating driven by balance sheet improvements and a possible short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the early commercial rollout of Yartemlea and anticipate further clarity on revenue ramp and European regulatory progress. The community remains focused on potential milestone payments from the partnership with Novo Nordisk and the company's long-term potential as a commercial-stage biotech, despite current frustration over recent share price volatility and limited official guidance.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility as investors weigh the company's exposure to ongoing tariff risks against its ambitious international expansion and long-term luxury strategy. The community remains deeply divided, with some traders betting on a short squeeze or a valuation recovery, while others express skepticism over the firm's leadership and the sustainability of its high-end furniture pricing in a strained economic environment.

THE FAMOUS DOG JUMPING INTO THE WATER FROM TIKTOK WITH 500M+ VIEWS.  A few facts about me - Signature Pool Dive - Serial Killer - Silly  Roadmap 1. BORN - Launch of a token, development of a family of holders and a twitter 2.BORN - Project development, marketing and connect KOLs 3. CEX listings - Listing on top exchanges and partnerships  Being a memecoin doesn’t mean we won’t have utilities. Our developers will develop some fun and useful tools for its community members as we continue to BUIDL! Our main goal is to make sure everyone has access to our utilities, so we build it with scalability in mind.  Ready to Splash?

Splash Dog

BUSTER CRYPTO is gaining momentum within the Solana ecosystem as community members rally behind the token and express strong bullish sentiment regarding its growth potential.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense community scrutiny and volatility as investors weigh the company's long-term promise in photonics against a lack of concrete revenue milestones ahead of upcoming financial reports. While bulls point to high-profile ecosystem partnerships and potential for massive scaling by 2027, bears remain focused on the company's history of dilution and the absence of significant, publicly disclosed production orders, keeping market sentiment cautious.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is driving significant engagement through a coordinated social campaign to increase visibility and brand awareness. Discussions are largely centered around community building, frequent meme-style interaction, and encouraging new participants to join their ecosystem.

Tema ETF Trust - Tema Space Innovators ETF

Investors are gaining exposure to the broader space economy through this newly listed ETF, with community discussions centering on its strategic holdings in key industry players and comparisons to other space-focused stocks.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is facing significant scrutiny as the community highlights recent health code violations, including a vermin infestation, alongside ongoing debates about the company's financial sustainability and weakening competitive position against at-home entertainment. Investors are actively discussing the stock's high short interest and its potential for volatility, with many expressing skepticism about management's turnaround strategy amidst poor operational performance.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is drawing intense community attention due to a strategic clinical development collaboration with Pfizer for its multiple myeloma candidate, which includes a 25 million dollar equity investment at a premium. Investors are actively debating the stock's potential for a short squeeze given the high short interest and institutional backing, with many focusing on the validation this deal provides for the company's oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quince Therapeutics Stock Climbs 8% Over Payment Of $5.5 Mln To Settle EIB Loan

(RTTNews) - Shares of Quince Therapeutics, Inc. (QNCX) are moving up about 8 percent on Monday morning trading after the company announced the settlement of its outstanding obligations under its loan from the European Investment Bank for a payment of $5.5 million...

<ul class="summary-bullets"><li>Quince Therapeutics paid $5.5 million to settle its total debt worth $16.4 million.</li><li>The company had earlier said that it has a runway up to the second half of 2026 if its warrants are exercised.</li><li>The stock has tanked 97% since the company announced disappointing trial results for its treatment of a rare nervous system disorder.</li></ul>Shares of Quince Therapeutics (QNCX) gave up most of their pre-market gains, but traded with almost 10% gains on Monday morning after the company announced it has settled its debt with the European Investment Bank, a move that clears the way for advancing its restructuring efforts.Quince Therapeutics said it paid $5.5 million and, as a result, has settled its total debt worth $16.4 million. With this payment, all commitments under both the loan and settlement agreements have been fully satisfied.“By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives, including, but not limited to, merger, reverse merger, asset sale, or other strategic transactions,” said CEO Dirk Thye.&nbsp;The company had earlier appointed LifeSci Capital as its exclusive financial advisor to assist with the restructuring.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.Users speculated a potential merger after the debt was cleared.<stembedurl>https://stocktwits.com/SuellenD/message/648925162</stembedurl><stembedurl>https://stocktwits.com/andrew011/message/648923227</stembedurl><h2 class="st-heading-2">Stock Sinks After Disappointing Phase 3 Results</h2>In January, Quince Therapeutics’ Phase 3 NEAT trial evaluating eDSP in patients with Ataxia-Telangiectasia, a rare disorder impacting the nervous and immune systems, missed its primary and key secondary endpoints. <a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has since crashed more than 97%.According to its last financial filing for the quarter ended Sept. 30, 2025, the company reported $26.3 million in cash and investments. The funds are expected to support operations through the second quarter of 2026, but could be extended into the second half of 2026 if its warrants are fully exercised.Last year, the company raised about $11.5 million in upfront funding through a financing round, with the potential to secure an additional $10.4 million if the associated warrants are fully exercised for cash.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger

Quince Therapeutics Inc (QNCX) cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Equity

The company cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the companys outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5...

What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours

Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans. read more...

Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today

QNCX, SPOT, SPGI, INTC, DDOG were among the stocks trending among investors on Tuesday, Feb. 10, 2026.read more...

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic...

Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease

Quince Therapeutics shares plunged nearly 90% after its Phase 3 trial for a rare genetic disorder missed primary and secondary goals, despite showing no major safety concerns.read more...

Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp

Citizens Jmp cut shares of Quince Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday...

<ul class="summary-bullets"><li>Quince on Thursday announced that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.</li><li>The study further did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;</li></ul> Shares of Quince Therapeutics, Inc. (QNCX) closed 92% lower on Thursday after the company said that it has decided to cease clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).Quince <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260129349326/en/Quince-Therapeutics-Announces-Topline-Results-from-Pivotal-Phase-3-NEAT-Clinical-Trial-of-eDSP-in-Ataxia-Telangiectasia">announced</a> that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.Moreover, the study did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;<h2 class="st-heading-2">What Is Ataxia-Telangiectasia?</h2>Ataxia-Telangiectasia (A-T) is a rare, inherited neurodegenerative disorder caused by mutations in the ATM gene, leading to progressive loss of coordination, small, visible blood vessels in the eyes/skin, a weakened immune system, and a high risk of cancer, typically appearing in early childhood with unsteady walking and balance issues.Patients with the condition have a median lifespan of approximately 25 to 30 years. There are no approved therapies for the disorder in any global market, as per Quince, though there are about 4,600 diagnosed patients with A-T in the U.S.Shares of the company edged up 2% after hours at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around QNCX shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user said that they are adding more shares in the company for the “epic return to glory.”<stembedurl>https://www.stocktwits.com/McGinvests/message/643354295</stembedurl>Another user termed the selloff as “brutal” and hinted at a possible bankruptcy filing.<stembedurl>https://www.stocktwits.com/SierraIndiaDavid/message/643354859</stembedurl><a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has lost 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krro-shares-jump-on-analyst-upgrades/cmyimzWR41O">KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Why Did QNCX Stock Plummet Over 90% Today?

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Quince Therapeutics Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$0.1014
Prev Close	$0.1013
Open	$0.10
Dividend Yield	0.00%
50-Day Moving Average	$0.647
Beta	1.03
Avg. Volume	175.77M
PE Ratio	-0.08

52-Week High	$4.55
52-Week Low	$0.08
Market Capitalization	$5.64M
EPS (Annual)	-$1.31
Price to Book	5.21
Revenue Per Employee	$0.00

QNCX
Quince Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QNCX News

QNCXQuince Therapeutics Inc